LEUKO LABS, INC.

BOSTON, MA · Founded 2017 · Medtech · Private

PointCheck, a non-invasive optical imaging device that monitors microcirculation in nailfold capillaries to detect severe neutropenia in cancer chemotherapy patients

Claim this profile

Follows are private to you and power your alerts

Updated · leuko.com

Sector
Medtech
Headquarters
BOSTON, MA
Founded
2017
Latest Form D
$1.2M, Feb 2019
Total capital
$7M
Federal grants
$5.8M
6 awards · 2018–2025
Rank in peer group#95 of 538
Private capital raised
$1.2M
1 Form D · last Feb 2019
92 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
4
5 pending · first 2024
Rank in peer group#125 of 538

Capital timeline

20182019202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $7M$214K$55K$1.2M$806K$1.7M$1.8M1st Form D$1.2M
2018202020222024FEDERAL ↑EQUITY ↓Cumulative $7M$1.2M$806K$1.7M$1.8M1st Form D$1.2M

Latest events

  • Federal grantHealth and Human S · Phase II · Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$1.8M
  • Federal grantHealth and Human S · Phase II · Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$1.7M
  • Federal grantHealth and Human S · Phase II · Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$806K
  • Federal grantHealth and Human S · Phase II · Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$1.2M
  • Federal grantHealth and Human S · Phase I · Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$55K
  • Private capital raisedForm D · SEC · 1st filing$1.2M
  • Federal grantHealth and Human S · Phase I · Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$214K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

7months

from LEUKO LABS, INC.’s first federal award to its first private round.

First federal award · Jul 2018
Health and Human S · $214K
First Form D · Feb 2019
$1.2M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 538 peers

Line = median

Medtech · Device

  • Federal grants#95 · top 18%
  • Granted patents#125 · top 23%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Ian Castro ButterworthResearcherExecutive Officer, DirectorLinked by 2 patents
  • Amy Castro SalzhauerDirectorNamed in SEC Form D filings
  • Carlos Castro GonzalezExecutive Officer, DirectorNamed in SEC Form D filings
  • Paul Castro HartungDirectorNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 9
Show all 9 patent records
  • CENTERLINE BIOMEDICAL INCSimilar federal contract value in Medtech · null in contracts
  • PolyK Technologies, LLCSimilar federal contract value in Medtech · null in contracts
  • METRITRACK, INC.Similar federal contract value in Medtech · null in contracts
  • Adm Diagnostics, Inc.Similar federal contract value in Medtech · null in contracts
  • AxoGen, Inc.Similar federal contract value in Medtech · null in contracts
  • PrimeraDx, Inc.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .